Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $9.38 in the last session, down -1.88% from day before closing price of $9.56. In other words, the price has decreased by -$1.88 from its previous closing price. On the day, 2.73 million shares were traded. NTLA stock price reached its highest trading level at $9.675 during the session, while it also had its lowest trading level at $9.33.
Ratios:
We take a closer look at NTLA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 29 ’25 when Bhanji Muna sold 265 shares for $8.50 per share. The transaction valued at 2,252 led to the insider holds 19,203 shares of the business.
Clark Eliana sold 679 shares of NTLA for $6,104 on Mar 04 ’25. The EVP, Chief Technical Officer now owns 95,369 shares after completing the transaction at $8.99 per share. On Mar 04 ’25, another insider, BASTA JAMES, who serves as the EVP, General Counsel of the company, sold 2,572 shares for $8.99 each. As a result, the insider received 23,122 and left with 111,925 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 971608576 and an Enterprise Value of 587118208. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.32 while its Price-to-Book (P/B) ratio in mrq is 1.25. Its current Enterprise Value per Revenue stands at 12.884 whereas that against EBITDA is -1.106.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.21, which has changed by -0.57652366 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.18, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 10.13%, while the 200-Day Moving Average is calculated to be -22.29%.
Shares Statistics:
According to the various share statistics, NTLA traded on average about 4.49M shares per day over the past 3-months and 4951460 shares per day over the past 10 days. A total of 103.54M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.95% of the company’s shares, while institutions hold 92.21% stake in the company. Shares short for NTLA as of 1749772800 were 29689496 with a Short Ratio of 6.61, compared to 1747267200 on 30704048. Therefore, it implies a Short% of Shares Outstanding of 29689496 and a Short% of Float of 32.630002000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
